{"disease":{"id":"candida-peritonitis","name":"Candida Peritonitis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"fluconazole","indication_name":"Candida peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"caspofungin","indication_name":"Candida Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cancidas","generic_name":"CASPOFUNGIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Echinocandin Antifungal","quality_score":63,"revenue":null,"mechanism":"Cancidas works by inhibiting the synthesis of beta-1,6-glucan, a critical component of the fungal cell wall."},{"drug_id":"anidulafungin","indication_name":"Candida Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eraxis","generic_name":"ANIDULAFUNGIN","company_name":"Vicuron Holdings","drug_phase":"marketed","molecular_target":"","drug_class":"Echinocandin Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":"Eraxis works by inhibiting the synthesis of beta-1,3-D-glucan, a critical component of the fungal cell wall."},{"drug_id":"micafungin","indication_name":"Candida Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycamine","generic_name":"MICAFUNGIN","company_name":"Teva Pharms Usa Inc","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Echinocandin Antifungal","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Candida Peritonitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00802854","title":"Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV","phase":"","overall_status":"COMPLETED","enrollment_count":244,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07005258","title":"Diagnostic Performance of the CandID PLUS PCR for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients","phase":"","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05264571","title":"Early Identification of Candida in Intra-abdominal Candidiasis","phase":"","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}